AVECTAS Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 33

Employees
  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $20.2M

  • Investors
  • 4

AVECTAS General Information

Description

Developer of non-viral and cell engineering technology designed to improve the cost, manufacturing, and patient outcomes for the next generation of cellular therapies. The company's technology permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality, enabling drug developers to develop potent engineered cell therapies at therapeutic volumes with minimal cell disruption.

Contact Information

Website
www.avectas.com
Formerly Known As
Profector Life Sciences
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • 3rd Floor Eolas Building
  • Kildare, MaynoothWorks, Maynooth University
  • Maynooth
  • Ireland

AVECTAS Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AVECTAS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series C) 16-Apr-2020 $20.2M 000.00 000.00 Completed Generating Revenue
7. Later Stage VC 09-Apr-2019 00.00 000.00 000.00 Completed Generating Revenue
6. Later Stage VC 27-Apr-2018 00.000 000.00 000.00 Completed Generating Revenue
5. Grant 01-Feb-2018 00.000 000.00 Completed Generating Revenue
4. Later Stage VC 21-Apr-2017 00.000 000.00 000.00 Completed Generating Revenue
3. Corporate 05-Jan-2015 0000 000.00 Completed Generating Revenue
2. Early Stage VC 14-Nov-2014 $2.37M $2.7M 00.000 Completed Startup
1. Early Stage VC 09-Oct-2013 $473K $338K 00.000 Completed Startup
To view AVECTAS’s complete valuation and funding history, request access »

AVECTAS Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 00,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 197,800 $0.010904 $1.27 $1.27 1x $1.27 0.9%
Ordinary 105,000 $0.010904 $1.55 $1.55 1x $1.55 0.48%
To view AVECTAS’s complete cap table history, request access »

AVECTAS Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of non-viral and cell engineering technology designed to improve the cost, manufacturing, and patient outcomes
Drug Delivery
Maynooth, Ireland
33 As of 2022
000.00
00.00 0000-00-00
00000000000 000.00

000000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conseq
000000000 00000 (0000000000)
Milpitas, CA
00 As of 0000
000.00
0000000000 000.00

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
0000000000000
Tucson, AZ
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AVECTAS Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Applied StemCell Venture Capital-Backed Milpitas, CA 00 000.00 0000000000 000.00
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000
00000000 Venture Capital-Backed Redwood City, CA 000 00000 00000000000 00000
00000 0000 0000 Venture Capital-Backed Pittsburgh, PA 0 00.000 0000000000 0 00.000
You’re viewing 5 of 12 competitors. Get the full list »

AVECTAS Patents

AVECTAS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210290757-A1 Engineering of dendritic cells for generation of vaccines against sars-cov-2 Pending 23-Mar-2020 0000000000
US-20210254097-A1 Engineering of immune cells for ex vivo cell therapy applications Pending 06-Sep-2019 000000000
US-20210261901-A1 Cell engineering platform Pending 01-Jun-2018 000000000
EP-3802779-A1 Cell engineering platform Pending 01-Jun-2018 000000000
US-20210284945-A1 Cell engineering platform Pending 01-Jun-2018 C12M35/08
To view AVECTAS’s complete patent history, request access »

AVECTAS Executive Team (6)

Name Title Board Seat Contact Info
Michael Maguire Ph.D Co-Founder, Chief Executive Officer & Executive Board Member
Shirley O'Dea Ph.D Academic Founder, Chief Scientific Officer & Executive Board Member
Eoin Heffernan Director of Finance & Strategic Operations
Daniel Castro Chief Business Officer
Mary Martin Ph.D Executive Chairwoman
You’re viewing 5 of 6 executive team members. Get the full list »

AVECTAS Board Members (7)

Name Representing Role Since
Ann Brady Ph.D Self Board Member 000 0000
Barry Leonard AVECTAS Board Member 000 0000
Barry Wohl Self Board Member 000 0000
Eunan Maguire Adapt Pharma Board Member 000 0000
Mary Martin Ph.D AVECTAS Executive Chairwoman 000 0000
You’re viewing 5 of 7 board members. Get the full list »

AVECTAS Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AVECTAS Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seamus Mulligan Angel (individual) Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Adapt Pharma Corporation Minority 000 0000 000000 0
David Brabazon Angel (individual) Minority 000 0000 000000 0
To view AVECTAS’s complete investors history, request access »